Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Sender HerschornDavid StaskinCarol R SchermerRita M KristyAdrian WaggPublished in: Drugs & aging (2020)
This study is registered at ClinicalTrials.gov: NCT02216214.